A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF

Summary

OBJECTIVES Primary: To evaluate efficacy of treatment with anakinra in subjects with CF who are ≥ 12 years of age by means of lung clearance index (LCI). Secondary To evaluate safety and tolerability of treatment with anakinra as well as to investigate further effects of anakinra on lung function and quality of life (QOL) in subjects with CF.

Timeline

Start

2022-12-01

Primary completion

2026-12-01

Completion

2026-12-01

Drugs

Indications